Luteolin Attenuates Diabetic Myocardial Hypertrophy by Inhibiting Proteasome Activity

Abstract

This study indicates that luteolin protected against DCM in mice, including T1DM and T2DM, by upregulating phosphorylated protein AMPK and AKT/GSK-3 pathways while decreasing the proteasome activity. These findings suggest that luteolin may be a potential therapeutic agent for DCM.